JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 23.72 Billion JPY | 15.82% |
| 2022 | 20.48 Billion JPY | -1.0% |
| 2021 | 20.68 Billion JPY | 47.73% |
| 2020 | 14 Billion JPY | 2.7% |
| 2019 | 13.63 Billion JPY | 17.29% |
| 2018 | 11.62 Billion JPY | 8.84% |
| 2017 | 10.68 Billion JPY | 6.9% |
| 2016 | 9.99 Billion JPY | 13.2% |
| 2015 | 8.82 Billion JPY | -3.01% |
| 2014 | 9.1 Billion JPY | 9.4% |
| 2013 | 8.31 Billion JPY | 5.14% |
| 2012 | 7.91 Billion JPY | 4.9% |
| 2011 | 7.54 Billion JPY | -3.59% |
| 2010 | 7.82 Billion JPY | -5.03% |
| 2009 | 8.23 Billion JPY | 3.22% |
| 2008 | 7.98 Billion JPY | 2.77% |
| 2007 | 7.76 Billion JPY | 31.84% |
| 2006 | 5.89 Billion JPY | 22.64% |
| 2005 | 4.8 Billion JPY | 20.47% |
| 2004 | 3.98 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 6.69 Billion JPY | 13.66% |
| 2024 Q1 | 6.36 Billion JPY | -4.58% |
| 2023 Q3 | 5.99 Billion JPY | -1.98% |
| 2023 Q4 | 6.23 Billion JPY | 4.0% |
| 2023 FY | 23.71 Billion JPY | 15.82% |
| 2023 Q1 | 5.37 Billion JPY | -4.58% |
| 2023 Q2 | 6.11 Billion JPY | 13.66% |
| 2022 Q4 | 5.63 Billion JPY | 16.37% |
| 2022 FY | 20.48 Billion JPY | -1.0% |
| 2022 Q1 | 5.13 Billion JPY | -8.27% |
| 2022 Q2 | 4.86 Billion JPY | -5.32% |
| 2022 Q3 | 4.84 Billion JPY | -0.39% |
| 2021 Q4 | 5.59 Billion JPY | 15.95% |
| 2021 Q3 | 4.82 Billion JPY | -13.05% |
| 2021 FY | 20.68 Billion JPY | 47.73% |
| 2021 Q1 | 4.7 Billion JPY | 8.29% |
| 2021 Q2 | 5.55 Billion JPY | 18.07% |
| 2020 Q3 | 3.52 Billion JPY | 8.05% |
| 2020 Q4 | 4.34 Billion JPY | 23.09% |
| 2020 FY | 14 Billion JPY | 2.7% |
| 2020 Q1 | 2.86 Billion JPY | -20.44% |
| 2020 Q2 | 3.26 Billion JPY | 14.04% |
| 2019 Q3 | 2.97 Billion JPY | -25.3% |
| 2019 Q2 | 3.97 Billion JPY | 28.83% |
| 2019 Q1 | 3.08 Billion JPY | -4.37% |
| 2019 FY | 13.63 Billion JPY | 17.29% |
| 2019 Q4 | 3.6 Billion JPY | 21.17% |
| 2018 FY | 11.62 Billion JPY | 8.84% |
| 2018 Q2 | 2.77 Billion JPY | 8.72% |
| 2018 Q3 | 3.06 Billion JPY | 10.18% |
| 2018 Q4 | 3.22 Billion JPY | 5.42% |
| 2018 Q1 | 2.55 Billion JPY | -14.54% |
| 2017 Q2 | 2.67 Billion JPY | 12.25% |
| 2017 FY | 10.68 Billion JPY | 6.9% |
| 2017 Q4 | 2.99 Billion JPY | 13.73% |
| 2017 Q3 | 2.63 Billion JPY | -1.72% |
| 2017 Q1 | 2.38 Billion JPY | -17.31% |
| 2016 Q2 | 2.38 Billion JPY | 7.88% |
| 2016 Q1 | 2.2 Billion JPY | -3.94% |
| 2016 FY | 9.99 Billion JPY | 13.2% |
| 2016 Q4 | 2.88 Billion JPY | 14.64% |
| 2016 Q3 | 2.51 Billion JPY | 5.51% |
| 2015 Q1 | 2.06 Billion JPY | -5.81% |
| 2015 Q4 | 2.3 Billion JPY | 17.02% |
| 2015 FY | 8.82 Billion JPY | -3.01% |
| 2015 Q3 | 1.96 Billion JPY | -21.09% |
| 2015 Q2 | 2.49 Billion JPY | 20.37% |
| 2014 FY | 9.1 Billion JPY | 9.4% |
| 2014 Q2 | 2.76 Billion JPY | 28.4% |
| 2014 Q3 | 1.98 Billion JPY | -28.1% |
| 2014 Q4 | 2.19 Billion JPY | 10.57% |
| 2014 Q1 | 2.15 Billion JPY | 0.64% |
| 2013 Q3 | 2.09 Billion JPY | -2.68% |
| 2013 Q4 | 2.13 Billion JPY | 2.29% |
| 2013 Q2 | 2.14 Billion JPY | 10.69% |
| 2013 Q1 | 1.94 Billion JPY | -6.73% |
| 2013 FY | 8.31 Billion JPY | 5.14% |
| 2012 Q2 | 1.93 Billion JPY | 0.58% |
| 2012 Q4 | 2.08 Billion JPY | 5.56% |
| 2012 FY | 7.91 Billion JPY | 4.9% |
| 2012 Q1 | 1.92 Billion JPY | 1.56% |
| 2012 Q3 | 1.97 Billion JPY | 1.83% |
| 2011 Q3 | 1.81 Billion JPY | -4.6% |
| 2011 Q2 | 1.9 Billion JPY | -1.2% |
| 2011 Q1 | 1.92 Billion JPY | -10.66% |
| 2011 FY | 7.54 Billion JPY | -3.59% |
| 2011 Q4 | 1.89 Billion JPY | 4.33% |
| 2010 Q1 | 1.86 Billion JPY | -14.61% |
| 2010 Q4 | 2.15 Billion JPY | 14.41% |
| 2010 FY | 7.82 Billion JPY | -5.03% |
| 2010 Q3 | 1.88 Billion JPY | -1.7% |
| 2010 Q2 | 1.91 Billion JPY | 2.96% |
| 2009 Q3 | 2.14 Billion JPY | 7.18% |
| 2009 Q4 | 2.18 Billion JPY | 1.84% |
| 2009 FY | 8.23 Billion JPY | 3.22% |
| 2009 Q2 | 1.99 Billion JPY | 4.33% |
| 2009 Q1 | 1.91 Billion JPY | -6.49% |
| 2008 Q4 | 2.04 Billion JPY | 4.91% |
| 2008 FY | 7.98 Billion JPY | 2.77% |
| 2008 Q3 | 1.95 Billion JPY | 1.53% |
| 2008 Q2 | 1.92 Billion JPY | 0.0% |
| 2007 FY | 7.76 Billion JPY | 31.84% |
| 2006 FY | 5.89 Billion JPY | 22.64% |
| 2005 FY | 4.8 Billion JPY | 20.47% |
| 2004 FY | 3.98 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 224.77 Billion JPY | 89.447% |
| Astellas Pharma Inc. | 1034.29 Billion JPY | 97.707% |
| Chugai Pharmaceutical Co., Ltd. | 258.88 Billion JPY | 90.838% |
| Ono Pharmaceutical Co., Ltd. | 212.44 Billion JPY | 88.835% |
| Santen Pharmaceutical Co., Ltd. | 111.97 Billion JPY | 78.816% |
| Daiichi Sankyo Company, Limited | 974.77 Billion JPY | 97.567% |
| Otsuka Holdings Co., Ltd. | 1115.15 Billion JPY | 97.873% |
| Perseus Proteomics Inc. | 982.41 Million JPY | -2314.461% |